Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Nezih Meydan"'
Autor:
Ozgur Tanriverdi, Eyup Murat Yilmaz, Serkan Menekse, Suna Cokmert, Esin Oktay, Kezban Nur Pilanci, Muharrem Kocar, Nilufer Avci, Tulay Akman, Gamze Goksel, Nezih Meydan, Sabri Barutca
Publikováno v:
Journal of Oncological Sciences, Vol 2, Iss 2, Pp 48-52 (2016)
Background: This study aimed to identify the risk factors related in recurrence with isolated intra-abdominal lymph node metastasis in patients with colorectal cancer. Methods: This is a retrospective, cross-sectional study of 21 colorectal cancer pa
Externí odkaz:
https://doaj.org/article/104db83b76c4453a9e348245916787fb
Autor:
Neslihan Soysal Atile, Nezih Meydan, Muharrem Balkaya, İbrahim Meteoğlu, Cengiz Ünsal, Bülent Bilir
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 4, Iss 1, Pp 29-38 (2016)
AimTo constitute an experimental rat model by using human VEGF monoclonal antibody bevacizumab, for observation of renal side effects of this treatment.Materials and MethodsThirtysix adult female Wistar albino rats has been divided as two main groups
Externí odkaz:
https://doaj.org/article/20884492e2ae44c7a387b361881d66fb
Publikováno v:
Cardiology Research and Practice, Vol 2018 (2018)
Aims. Cardiovascular diseases are the primary cause of premature morbidity and mortality in early breast cancer patients after treatment with cardiotoxic chemotherapeutic agents. Arterial stiffness is an independent risk factor for future cardiovascu
Externí odkaz:
https://doaj.org/article/89e3c01e45aa43a890438dab2927a86d
Publikováno v:
European Journal of Breast Health, Vol 7, Iss 3, Pp 188-190 (2011)
While cardiac toxicity due to chemotherapeutic agents is rare, it is a major cause of mortality. The most frequent cardiac toxicity is myocardial cell damage and particularly left ventricular ejection fraction reduction, which is due to anthracycline
Externí odkaz:
https://doaj.org/article/c6e6a95ca20342f29c6d2facc4765d83
Publikováno v:
European Journal of Breast Health, Vol 2, Iss 1, Pp 31-33 (2006)
Chemotherapy-induced menopause is a well-known condition in breast cancer patients. This menopausal state is usually reversible in younger women and those who had been treated by anthracyclines. Here, we report a 36-year old woman who had a history o
Externí odkaz:
https://doaj.org/article/47f65b7fd9ca48b88af1c4a90d88fb13
Publikováno v:
Case Reports in Oncological Medicine, Vol 2013 (2013)
Trastuzumab treatment does not prevent intracranial seeding and is largely ineffective for established central nervous system metastasis in HER2 overexpressing breast cancer patients. Combination therapy of lapatinib and capecitabine may be an effect
Externí odkaz:
https://doaj.org/article/715e8daacfae4710be01f94c5b4b9b53
Publikováno v:
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 86
The Controlling Nutritional Status (CONUT) Score, a new parameter that reflects the immuno-nutritional status, has been closely associated with prognosis in many cancer types. However, the prognostic significance of the CONUT score in Glioblastoma Mu
Autor:
Irfan Cicin, Mehmet Artac, Feyyaz Ozdemir, Metin Ozkan, Mustafa Benekli, Nezih Meydan, Sadettin Kilickap, Alper Sevinc, Abdurrahman Isikdogan, Faysal Dane, Mehmet Aliustaoglu, Berna Oksuzoglu, Mahmut Gumus, Emin Tamer Elkiran, Ozgur Ozyilkan
Objective Cytokines have been the mainstay of treatment in metastatic renal cell cancer (mRCC) for decades before the introduction of tyrosine kinase inhibitors (TKIs), which dramatically changed the therapeutic landscape in these patients. This obse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3237934761fbe92e804509ecf1df16b7
https://avesis.erciyes.edu.tr/publication/details/761eac20-9e0e-4edb-92dc-e3cf38ba25d0/oai
https://avesis.erciyes.edu.tr/publication/details/761eac20-9e0e-4edb-92dc-e3cf38ba25d0/oai
Autor:
Taşkın Şentürk, Hakan Akdam, Alper Alp, Nezih Meydan, Yavuz Yenicerioglu, Sabri Barutca, Ibrahim Meteoglu
Publikováno v:
Gazzetta Medica Italiana Archivio per le Scienze Mediche. 179
Autor:
Deniz Tural, Terry L. Ng, Noemi Reguart, Ömer Fatih Ölmez, Ozgur Ozyilkan, Ahmet Sezer, Ilhan Oztop, Mehmet Ali Kaplan, Laila C. Roisman, E. Filippova, Irfan Cicin, Aziz Karaoglu, Umut Demirci, Petros Christopoulos, Elizabeth Dudnik, Fatma Buğdaycı Başal, Perran Fulden Yumuk, D.R. Camidge, Sergei V. Orlov, Mehmet Ali Nahit Sendur, Nezih Meydan, Saadettin Kilickap, Mustafa Erman, Oliver Gautschi, Havva Yesil Cinkir, Patrizia Froesch, Kerem Okutur, Ismail Beypinar, Nir Peled, Kübra Aydın, Devrim Cabuk, Julien Mazieres, Hasan Şenol Coşkun, Alisan Zirtiloglu, Hande Turna, Taner Korkmaz, Abdurrahman Isikdogan, Roni Gillis, Ahmet Demirkazik, R. Grinberg, Doğan Yazılıtaş, Cengiz Yilmaz, Adnan Aydiner, Yesim Eralp, Semra Paydas, Filiz Çay Şenler, Ibrahim Yildiz, Moiseenko Fedor
Publikováno v:
Web of Science
Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. the FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we present the largest real-world d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa5766b0b6f75e47142bb5ab9ba635fc
https://hdl.handle.net/11454/61883
https://hdl.handle.net/11454/61883